Publish date:

What You Need to Know About La Jolla's Shock-Treatment Drug

LJPC-501 is a proprietary formulation of a protein that helps to regulate blood pressure.

After finding success in a phase III clinical trial of its shock-treatment drug LJPC-501, La Jolla Pharmaceuticals (LJPC) - Get La Jolla Pharmaceutical Company Report plans to submit a marketing application to the FDA in the second half of the year, pending a meeting with regulators. 

READ THE FULL STORY HERE: La Jolla Pharma Drug Raises Blood Pressure in Late-Stage Study of Shock Patients

This article was written by a staff member of TheStreet.

TheStreet Recommends